XyloCor Therapeutics raises $67.5 million in Series B financing
Jeito Capital leads the round alongside EQT, Fountain Healthcare Partners and Lumira Ventures. Proceeds fund two Phase 2 trials of gene therapy XC001 in refractory angina and as a CABG adjunct.